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Promise and complexity of lupus mouse models
As a follow up to a 2010 meeting deliberating on the benefits of studying mouse models of systemic lupus 
erythematosus (SLE), the virtual conference “Mouse models of lupus 10 years later” convened on 10 December 
2020 to address a challenging decade that saw few new therapies approved, despite leaps in knowledge.
Abnormalities in both innate and adaptive immunity characterize SLE, a systemic autoimmune disease 
with potentially severe consequences in 
patients. Treatment has traditionally been 
limited to broad-acting, side-effect-heavy 
immunosuppressants, which are also 
incompletely effective. Thus, the need for 
specific therapies targeting the pathogenic 
mechanisms of SLE remains unmet. 
Affirming the utility of mouse models in 
lupus research, a meeting convened in 
2010 recommended that the next decade’s 
research embrace these for their mechanistic 
insights; their diversity of phenotypes, 
which mirrors the heterogeneity observed 
among patients with lupus; and as a platform 
for clinical exploration. A decade later, 
hope persists; studies of murine models of 
lupus have uncovered putative therapies, 
and many were moved to clinical trials. 
Unfortunately, few interventions improved 
patient outcomes: belimumab was the sole 
therapy brought to market in the 2010s. 
The continuing difficulties in translating 
potential into success1–3 prompted a second 
conference, which was recorded.
On 10 December 2020, leading scientists 
and clinicians from all over the world, in 
partnership with the National Institutes of 
Health and the National Cancer Institute, 
gathered virtually. Hans-Joachim Anders 
(Ludwig Maximilian University of Munich) 
sparked much discussion with his opening 
address highlighting the multiple clinical 
trial design, diagnostic and scientific pitfalls 
that have seriously hindered translating 
success in lupus models to humans. Four 
scientific sessions followed, each delving 
into recent basic and translational advances 
in our understanding and treatment of SLE. 
In his closing keynote talk, Eric Morand 
(Monash University) proposed that the 
recent study of the interferon signature in 
SLE and the interventions it produced be 
used as a model for moving between human 
studies and mouse models, while stressing 
the scientific considerations needed to 
successfully utilize lupus models. Through 
discussions during the 2020 conference, 
participants aimed to revisit the utility of 
mouse models in the study of lupus by 
answering the following questions: Have 
animal models expanded our understanding 
of lupus pathogenesis? In what ways can we 
target the mediators of the lupus immune 
response? How has advanced technology 
been merged with the study of both lupus 
models and patients with lupus?
Infection and microbiome
Extraneous infection and the resident 
microbiome both act as routes through 
which a predisposed immune system may 
be hyperstimulated to precipitate loss of 
tolerance and trigger autoimmunity (Fig. 1). 
Mark Shlomchik (University of Pittsburgh) 
reported that experimental autoimmunity 
following Salmonella infection results from 
marked extrafollicular expansion of B cell 
populations, and the rapid maturation of 
B cells outside germinal centers increases 
autoantibody levels4. Interleukin (IL)-12 
mediates this extrafollicular-dominant 
autoimmune “storm” by suppressing 
follicular helper T (TFH) cells necessary for 
germinal center formation5, suggesting that 
IL-12 inhibition could treat patients with 
lupus who have similar immune responses.
Stefania Gallucci and Çağla Tükel (Temple 
University) introduced a specific microbial 
driver of autoantibody production. The 
amyloid–nucleic acid compound curli–DNA, 
an Enterobacteriaceae biofilm component, is 
found throughout the murine intestinal tract 
during Salmonella infection. Tükel provided 
evidence that curli–DNA may trigger 
autoimmunity once it enters the blood via 
the intestinal epithelia or when it is shed by 
biofilm-bearing catheters6. Gallucci’s group 
supported this hypothesis, showing that 
intraperitoneal injection of curli–DNA in 
lupus NZB×W/F1 mice increased circulating 
autoantibody and type I interferon (IFN) 
concentrations and activated macrophages 
and dendritic cells7. In addition to these 
hallmarks of SLE, curli–DNA appeared to 
induce B cell class switching independently 
of T cells. Finally, Gallucci described 
circulating anti-curli–DNA antibodies whose 
levels correlate with flares of active disease in 
patients with lupus8.
Supporting the hypothesis of a defective 
intestinal barrier exposing the immune 
system to microbiota and their products, 
Gregg Silverman (New York University) 
presented analyses of stool samples from 
patients with SLE that showed evidence 
of a more permeable gut. Additionally, his 
group characterized a new dysbiosis in 
patients with SLE, with skewing toward 

















Fig. 1 | Dysbiosis and gut permeability contribute to lupus disease. Expansion of pathogenic gut 
microbiota can lead to increased permeability of the gut epithelial barrier, providing a route through which 
bacteria and bacterial antigens can enter systemic circulation. The immune response to these foreign 
epitopes may generate self-reactive antibodies, such as anti-curli–DNA, and contribute to lupus pathology.
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fewer protective species. Serology from 
these patients showed antibodies that react 
to a bacterial cell wall lipoglycan, which 
correlated with active renal disease9. With 
this knowledge, Silverman’s group colonized 
germ-free C57BL/6 mice with R. gnavus 
bacteria and saw levels of serum R. gnavus 
DNA rise, accompanied by elevations in gut 
permeability and zonulin. Administration 
of larazotide, a tight-junction regulator, 
reduced gut permeability, suggesting that R. 
gnavus induces elevated zonulin and disrupts 
tight junctions to increase gut permeability.
Similarly, Martin Kriegel (Yale University) 
presented evidence from both mice and 
human studies that Enterococcus gallinarum 
induces a more permeable gut, enabling its 
transmigration to the liver and lymph nodes. 
Significant immune activation, including 
rising type I IFN levels and anti-E. gallinarum 
antibodies, accompanies this process10. 
Interestingly, Kriegel’s group developed a 
vaccine that is able to suppress transmigration 
of E. gallinarum, which could be a new 
treatment strategy for autoimmunity related 
to microbiome dysbiosis.
Xin Luo (Virginia Tech University) 
characterized the microbiome of diseased 
MRL/lpr mice; more Lachnospiraceae 
and fewer Lactobacillaceae were found11, 
representing another pathogenic dysbiosis. 
The putatively protective Lactobacillaceae 
were then gavage delivered to female MRL/lpr 
mice, resulting in improved systemic and 
renal disease later in life12. Oral administration 
of vancomycin lessened or worsened lupus 
whether given before or after disease onset, 
respectively, suggesting different mechanistic 
effects on the immune system13.
Daniel Zegarra-Ruiz (Memorial Sloan 
Kettering Cancer Center) presented 
additional findings that point to diet as a 
contributing factor in murine dysbiosis and 
lupus. High fiber content in the diets of 
Toll-like receptor 7–transgenic mice resolved 
the dysbiosis that contributed to increased 
gut permeability and a lupus phenotype14.
The roles of infection, the microbiome, 
gut permeability and systemic bacterial 
products in lupus pathogenesis are only 
just being appreciated; nevertheless, strong 
evidence points to robust and far-reaching 
effects of dysbiosis in mice and humans who 
are predisposed. While it is impractical to 
sterilize and then specifically reconstitute 
the human microbiome, researchers may 
longitudinally characterize and manipulate 
a simulated human microbiome in mice 
as well as evaluate its relationship with 
disease onset. Mouse models, therefore, 
are fundamental to advancing our 
understanding of the interaction between 
bacteria and the immune system in SLE.
Identifying and repurposing drug targets
Recent advances presented at the meeting 
identified new drug targets and repurposed 
therapies for use in SLE. Both Mariana 
Kaplan (National Institute of Arthritis and 
Musculoskeletal and Skin Diseases) and 
Laurence Morel (University of Florida) 
demonstrated how targeting immune 
metabolism, specifically mitochondrial 
respiration, could improve disease burden in 
patients with SLE. Morel presented data for 
both humans and mice with SLE, showing 
that metformin, widely used to treat type 
2 diabetes, reduced prednisone use and 
decreased the number of flares in SLE15. 
Metformin’s debated mechanisms of action 
not only affect the AMPK–mTOR–STAT3 
pathway, but also, potentially, the electron 
transport chain, by inhibiting complex I. 
As a result, metformin reduces oxidative 
phosphorylation in CD4+ T cells isolated 
from patients with lupus and decreases IFN-γ 
production. This finding was recapitulated in 
Sle1Sle2Sle3 mice, but effects varied in other 
lupus mouse models, which is potentially 
indicative of strain-specific mechanisms 
involving mitochondrial respiration16.
Another repurposed drug, presented 
by Kaplan, demonstrated the benefit of 
targeting mitochondrial dysfunction to 
reduce aberrant apoptosis that occurs in 
SLE. Used in clinical trials for muscular 
dystrophies and neuropathies, idebenone 
acts as an antioxidant that bypasses complex 
I activity and enhances ATP synthesis. 
Without suppressing the immune system, 
idebenone improved renal disease in 
both the MRL/lpr and NZM2328 strains, 
decreased mitochondrial ROS production 
and neutrophil extracellular trap formation, 
and attenuated vasculopathy17. Similar 
findings were observed with the use of 
Mito-Q, another mitochondrial antioxidant, 
in MRL/lpr mice. These findings, along 
with Morel’s, demonstrate the potential of 
targeting immunometabolism in SLE.
The prospect of using anti-hypertensive 
angiotensinogen-converting enzyme (ACE) 
inhibitors to treat neuropsychiatric lupus 
manifestations was presented by Betty 
Diamond (Feinstein Institute). Building 
upon increased brain parenchymal ACE 
expression in lupus mice, Diamond 
demonstrated that administration of ACE 
inhibitors led to decreased microglial 
activation, prevented dendritic loss by 
increasing expression of the inhibitory 
receptor LAIR-1 and improved cognition in 
lupus mice18. Furthermore, in conjunction 
with human evidence indicating that ACE 
polymorphisms are associated with SLE, 
these findings demonstrate that modulating 
microglia by ACE inhibition is a beneficial 
repurposed therapy for patients with 
neuropsychiatric lupus.
Chaim Putterman (Azrieli Faculty 
of Medicine) discussed the potential of 
targeting CD6–ALCAM (activated leukocyte 
cell adhesion molecule) interactions, 
which are involved in the costimulation 
and activation of T cells as well as the 






Fig. 2 | the potential application of t cell phenotyping and tCr sequence monitoring at both the organ 
and disease levels. T cells play a key role in organ damage caused by lupus disease. Sequencing of a 
T cell receptor could potentially reveal its cognate antigen, including autoantigens. TCRs can be disease 
and organ specific, so monitoring a patient’s TCR repertoire could not only enable a lupus diagnosis but 
could also reveal organs potentially involved in the patient’s disease.
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Itolizumab is a monoclonal antibody 
targeting CD6 that blocks CD6–ALCAM 
interactions without depleting T cells. 
In patients with SLE, urinary ALCAM 
concentrations are elevated, particularly 
in those with active lupus nephritis, and 
are strongly correlated with SLE disease 
activity index scores, glomerular filtration 
rate and complement concentrations, and 
thus could serve as a potential biomarker 
for stratifying patients19. In MRL/lpr mice, 
anti-CD6 treatment improved renal disease, 
survival and extra-renal disease, such as 
skin histopathology20. Subsequently, a phase 
1b clinical trial with itolizumab has been 
initiated for SLE and lupus nephritis, in 
which urinary ALCAM and/or CD6 will 
be followed to determine whether these 
biomarkers can predict responsiveness to 
itolizumab (NCT04128579).
Recent advances have not only identified 
new drug targets but have also elucidated 
potential adverse mechanisms contributing 
to drug-induced lupus or autoimmunity, 
as has been observed for tumor necrosis 
factor (TNF) inhibitors. Tam Quach 
(Feinstein Institute) highlighted the varying 
mechanisms leading to autoantibody 
production in different mouse models 
lacking TNF, including extrafollicular 
pathways, the induction of memory cells, and 
aberrant germinal center formation. Quach 
suggested that TNF may also influence 
negative regulatory B cell functions, and 
thus its deletion results in a change in the 
threshold for the deletion of autoreactive 
B cells, leading to disease acceleration and 
increased mortality in permissive models.
Across human and mouse SLE data, there 
are a number of emerging drug targets, new 
or repurposed, that show promise and should 
be further evaluated. Furthermore, additional 
mouse model studies may reveal select stages 
in lupus in which specific therapies would 
have the greatest beneficial effect.
New technologies
In the past 10 years, innovative techniques 
such as the CRISPR–Cas9 system and 
single-cell RNA sequencing have broadly 
improved the ability to test hypotheses 
in disease models, shed new light on 
established concepts in SLE, and highlight 
the similarities and differences between 
lupus mouse models and patients with SLE. 
Eric Meffre (Yale University) investigated 
the mechanisms contributing to defective 
central B cell tolerance by using humanized 
mice grafted with hematopoietic stem 
cells21. In particular, the role of the tyrosine 
phosphatase PTPN22, encoded by a risk 
allele in SLE, was evaluated for its potential 
contribution to the loss of tolerance. 
Interestingly, blockade of PTPN22 in mice 
humanized with SLE hematopoietic stem 
cells corrected the loss of central tolerance 
even when the risk allele was absent. Meffre 
suggested that increased receptor editing 
may account for the improvement.
In discerning the mechanisms 
contributing to skin manifestations in 
lupus, Mitra Maz (University of Michigan) 
demonstrated differential type I IFN–
dependent immune responses in the skin of 
lupus mice following UVB exposure, leading 
to the subsequent recruitment of monocyte 
and macrophage populations. This work 
complements previous reports that even 
lupus keratinocytes from non-lesional 
skin display a type I IFN signature22, thus 
highlighting the complex interplay between 
IFNs and both immune and stromal cells in 
the pathogenesis of discoid lupus.
Another emerging avenue for research 
includes the evaluation of altered homeostatic 
pathways, such as circadian rhythms, in 
lupus. Anne Davidson (Feinstein Institute) 
presented on how the kidney-specific 
circadian rhythm of renal homeostatic 
functions, such as metabolism and blood 
pressure regulation, are disrupted in nephritic 
NZB×W/F1 lupus mice. Once remission is 
induced, partial corrections in glycolysis, 
vascular remodeling and regeneration and 
reversal of the abnormal blood pressure 
dipping pattern were observed in these 
mice, causing their reversion to a younger, 
healthier phenotype23. Davidson suggested 
that renal circadian rhythms, including 
urinary electrolyte excretion and blood 
pressure, measured through ambulatory 
blood pressure monitoring, could be tested 
as disease biomarkers and may also help 
dictate when specific therapeutics should 
be administered to correspond with a target 
organ’s internal processes.
Deepak Rao (Brigham and Women’s 
Hospital) highlighted work from the 
Accelerating Medicines Partnership network 
characterizing the adaptive immune cells in 
the kidneys of patients with lupus nephritis 
and discussed the expansion of CD4+ T cells 
among peripheral blood mononuclear cells 
from patients with SLE. PD-1hiCXCR5– 
peripheral helper T (TPH) cells were 
identified and shown to mediate B cell help 
in a manner dependent on the transcription 
factor MAF24. With a similar transcriptomic 
signature as that in TFH cells, emerging 
evidence has identified the presence of TPH 
cells in the pristane-induced lupus model. A 
benefit of mouse models highlighted by Rao 
is the ability to use the CRISPR–Cas9 and 
Cre/loxP systems to elucidate the various 
contributions similar and/or unique TFH and 
TPH cell markers make to the cell’s function.
Further functional characterization of 
TFH cells in SLE indicated the enhanced 
role of STAT4 in the secretion of IL-21 and 
IFN-γ. Jason Weinstein (Rutgers University) 
demonstrated that mouse lupus TFH cells 
develop a hyper-responsiveness to STAT4 
activation over time that maintains cytokine 
production, despite no observed increase 
in the expression of either IFN receptors 
or STAT4 itself25. Similar results were 
observed in a cluster of circulating TFH-like 
cells in patients with lupus, along with the 





























Evaluate efficacy in identified
patient subcluster
Fig. 3 | using overlapping disease signatures in appropriate mouse models and subclusters of 
patients with lupus for the development of targeted therapies. With advanced technology, it is 
possible to select specific mouse models that recapitulate the molecular features found in subgroups 
of patients with lupus. The insights and therapies resulting from studying these high-fidelity models 
should be translated back to their matching patient subgroups, increasing the likelihood of improving 
patient care.
Nature ImmuNology | VOL 22 | JuNE 2021 | 683–686 | www.nature.com/natureimmunology
686
meeting report
Erica Moore (Albert Einstein College  
of Medicine) highlighted similarities 
between the mouse and human T cell 
receptor (TCR) repertoires in SLE. Using 
CDR3 sequencing, enhanced sample 
clonality demonstrated the directed 
immune response present in patients 
with SLE as compared to healthy controls. 
Additional analysis of the TCR repertoires 
revealed a skewed use of V genes in both 
humans and mice and the potential to 
use select TCR sequences as biomarkers 
for diagnostic or prognostic purposes in 
patients with SLE26. Furthermore, select 
TCR sequences alongside T cell phenotyping 
could be used to monitor specific organ 
manifestations (Fig. 2), as highlighted 
by an identified consensus sequence in 
brain-infiltrating T cells in MRL/lpr mice 
with neuropsychiatric manifestations27.
Paul Hoover (Brigham and Women’s 
Hospital and Broad Institute) compared 
human SLE signatures and lupus mouse 
models using single-cell RNA sequencing. 
The characterization of myeloid cells in 
the kidneys of mice with lupus revealed 
that the main populations were residential 
macrophages, classical and non-classical 
monocytes and circulating dendritic cells 
in both Sle1Yaa and NZB/W models28. 
Based on differentially expressed gene 
profiles, a number of the myeloid signatures 
present in humans, excluding the resident 
macrophage cluster, were observed in the 
two mouse lupus models, and some were 
associated with nephritis. Furthermore, 
Hoover showed preliminary data suggesting 
that the monocyte subsets occupied similar 
kidney compartments in both mouse and 
human kidney tissue. Differences between 
the lupus mouse strains were suggested to 
mirror patient-specific phenotypes as well as 
different aspects of disease.
Improved methodologies can more readily 
elucidate mechanisms in greater detail and 
with nuance and can identify mouse models 
that may best match subsets of patients 
with SLE. While no singular mouse model 
recapitulates lupus disease in humans, 
these recent studies highlight overlapping 
mechanisms between patients with SLE 
and mouse models and the possibility 
of selectively using mouse models to 
appropriately query facets of SLE pathogenesis 
and develop new treatments (Fig. 3).
Concluding remarks
The meeting gathered early career and 
established scientists and clinicians to 
debate and discuss the usefulness of lupus 
mouse models. Through human and 
mouse data comparisons as well as lengthy 
discussions, the data presented showed 
that lupus mouse models still perform an 
irreplaceable function in modelling systemic 
autoimmunity and elucidating facets of 
disease pathogenesis. More specifically, 
experimental manipulations in these 
models have accelerated various avenues 
of research, including identifying internal 
triggers, via alterations in the microbiome; 
target-organ-specific mechanisms; 
and emerging drug targets, such as 
immunometabolism. Recognizing the 
heterogeneity of lupus manifestations and 
likely disease mechanisms, the consensus 
was to continue using lupus mouse models 
but to do so in a purposeful and directed 
manner, testing specific questions relevant 
to the particular model. Furthermore, 
technological advances will enhance our 
ability to first use findings in particular 
subsets of patients with SLE, which will 
guide the selection of mouse models and 
experiments in developing targeted therapies 
for the clinic. ❐
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